Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;29(2):73-83.
doi: 10.6118/jmm.22034.

Combination of Soy Isoflavones, 8-Prenylnaringenin and Melatonin Improves Hot Flashes and Health-Related Quality of Life Outcomes in Postmenopausal Women: Flavie Study

Affiliations

Combination of Soy Isoflavones, 8-Prenylnaringenin and Melatonin Improves Hot Flashes and Health-Related Quality of Life Outcomes in Postmenopausal Women: Flavie Study

Carmela Puchol Estrugo et al. J Menopausal Med. 2023 Aug.

Abstract

Objectives: This study aims to investigate the effects of a combination of soy isoflavones, 8-prenylnaringenin (8-PN), and melatonin in postmenopausal women suffering from moderate-to-severe hot flashes (HFs).

Methods: A multicenter, prospective, open-label study enrolled 44 postmenopausal women suffering from moderate-to-severe HFs (≥ 5 daily or ≥ 35 weekly) to receive 54.4 mg standardized soy isoflavones (including 24.5 mg genistein and 16.3 mg daidzein), 100 µg 8-PN, and 1 mg melatonin once daily for 12 weeks. The primary clinical outcomes included changes in health-related quality of life (HRQoL) scores (Menopause-Specific QoL questionnaire [MENQoL] and Cervantes Scale) and HFs following 4 and 12 weeks of treatment. Other analyses included treatment adherence, acceptability, tolerability, and safety.

Results: All of the four domains of MENQoL questionnaire significantly improved at 4 weeks (P < 0.05) and 12 weeks (P < 0.001), affecting significantly the vasomotor, psychosocial, and physical spheres (41.2%, 26.3%, and 25.0%; 12 weeks improvements, respectively). Similarly, in the menopause (39.3%) and psychic (51.7%) domains (both P < 0.05 at 12 weeks), the global score of the Cervantes Scale significantly increased at 4 weeks (18.6%) and 12 weeks (35.4%). Accordingly, moderate-to-severe HFs significantly decreased at 4 weeks compared to baseline (41.7% reduction) and further reduced at 12 weeks (76.5%), including the total number of episodes.

Conclusions: Food supplements containing soy isoflavones, 8-PN, and melatonin showed an early and progressive benefit for reducing clinically significant HFs and for improving HRQoL across all domains, favorably affecting postmenopausal women's overall well-being.

Keywords: 8-Prenylnaringenin; Hot flashes; Isoflavones; Menopause; Quality of life.

PubMed Disclaimer

Conflict of interest statement

PS-L and CNM are employees of ITalfarmaco Research Pharma SLU. NM-LG receives honoraria or consulting fees from Italfarmaco Research Pharma SLU, Astellas or Shionogi.

Figures

Fig. 1
Fig. 1. Reduction (%) in score in (A) Menopause-Specific Quality of Life Questionnaire (MENQoL) domains by timepoint (vs. baseline) and (B) Cervantes Scale domains by timepoint (vs. baseline). #P < 0.05 vs. baseline; ***P < 0.001 (12 weeks vs. 4 weeks). Reduction in these scores reflects QoL improvement.
Fig. 2
Fig. 2. Mean number ± SE of total (A) and by-intensity (B) weekly hot flashes by timepoint. #P < 0.001 vs. baseline; ***P < 0.001 (12 weeks vs. 4 weeks).

References

    1. Rees M, Abernethy K, Bachmann G, Bretz S, Ceausu I, Durmusoglu F, et al. The essential menopause curriculum for healthcare professionals: a European Menopause and Andropause Society (EMAS) position statement. Maturitas. 2022;158:70–77. - PubMed
    1. Bansal R, Aggarwal N. Menopausal hot flashes: a concise review. J Midlife Health. 2019;10:6–13. - PMC - PubMed
    1. Caan B, LaCroix AZ, Joffe H, Guthrie KA, Larson JC, Carpenter JS, et al. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause. 2015;22:607–615. - PMC - PubMed
    1. Delamater L, Santoro N. Management of the perimenopause. Clin Obstet Gynecol. 2018;61:419–432. - PMC - PubMed
    1. Jenabi E, Shobeiri F, Hazavehei SM, Roshanaei G. Assessment of questionnaire measuring quality of life in menopausal women: a systematic review. Oman Med J. 2015;30:151–156. - PMC - PubMed